Considerations for licensure of influenza vaccines with pandemic and prepandemic indications

Current Topics in Microbiology and Immunology

Volumn 333, Issue 1, 2009, Pages 453-470

  Baylor, Norman W ^a   Houn, Florence ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; IMMUNOGLOBULIN A ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; PANDEMIC INFLUENZA VACCINE; PLACEBO; SEASONAL INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG INDUSTRY; DRUG LEGISLATION; DRUG POTENCY; DRUG RESEARCH; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; INFLUENZA; LICENSING; PANDEMIC INFLUENZA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; SHELF LIFE; TREATMENT INDICATION;

AVES;

EID: 77950610795     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-92165-3_22     Document Type: Review

References (18)

1. Belshe RB, Gruber WC, Mendelman PM et al (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168-175
2. Bernstein DI, Edwards KM, Decker CL et al (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197(5):667-675
3. Code of Federal Regulations (CFR) (2007) Title 21 Food and Drugs. Office of the Federal Register, National Archives & Records Administration, Washington, DC
4. Committee for Proprietary Medicinal Products (CPMP) (1997) Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. The European Agency for the Evaluation of Medicinal Products (EMEA), London
5. Couch RB, Douglas RG, Rossen R, Kasel J (1969) Role of secretory antibody in influenza. In: The secretory immune system. US Dept Public Health, Washington, DC, pp 93-112
6. De Jong JC, Palache AM, Beyer WEP et al. (2003) Haemagglutination- inhibiting antibody to influenza virus. Dev Biol (Basel) 115:63-73
7. Fauci AS (2005) Testimony before the Committee on Foreign Relations, United States Senate: "Pandemic influenza: the road to preparedness." http://www.hhs.gov/asl/testify/t051109.html
8. FDA (2006) Draft Guidance for Industry: Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. US Food and Drug Administration, Rockville, MD
9. FDA (2007a) Guidance for Industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. US Food and Drug Administration, Rockville, MD
10. FDA 2007b) Guidance for Industry: Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration, Rockville, MD
11. Greenberg SB, Criswell BS, Couch RB (1975) Lymphocyte-mediated cytotoxicity against influenza virus-infected cells. An in vitro method. J Immunol 115:601-603
12. Hobson D, Curry RL, Beare AS, Ward-Gardner A (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Camb) 70:767-777
13. Piedra PA, Gaglani, MJ, Riggs M et al. (2005) Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 16:e397-e407
14. Rowe T, Abernathy RA, Hu-Primmer J et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37:937-943
15. Stephenson I, Bugarini R, Nicholson KG et al (2005) Cross-reactivity to highly pathogenic avian influenza viruses after vaccination with MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191:1210-1215
16. Treanor J, Keitel W, Belshe R et al. (2002) Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 20:1099-1105
17. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351
18. Wadman M (2005) Race is on for flu vaccine. Nature 438:23